RUA Life Sciences (GB:RUA)
LSE:RUA
Want to see GB:RUA full AI Analyst Report?
Top Page
RUA Life Sciences
(LSE:RUA)
Select Model
Select Model
Rating:60Neutral
Price Target:
19.00 p
▲(35.71% Upside)
Action:Reiterated
Date:05/10/26
The score is primarily constrained by ongoing operating losses and negative operating/free cash flow despite strong revenue growth and a low-leverage balance sheet. Technicals are supportive due to strong trend and positive MACD, but overbought signals add near-term risk. Valuation looks favorable based on the low P/E.
Positive Factors
Sustained Revenue Scale-Up
Multi-year revenue expansion demonstrates the company is scaling commercial adoption and manufacturing throughput. Persistent top-line growth supports capacity utilization, long-term supplier/customer relationships and provides the foundation to absorb fixed costs and pursue margin improvement as the business matures.
Negative Factors
Persistent Negative Cash Flow
Continued negative operating and free cash flow means the business is not yet self-funding; this creates dependency on external financing to sustain growth. Over 2–6 months this elevates execution risk if capital markets tighten and can force dilution, cutbacks, or slower reinvestment in critical capabilities.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Scale-Up
Multi-year revenue expansion demonstrates the company is scaling commercial adoption and manufacturing throughput. Persistent top-line growth supports capacity utilization, long-term supplier/customer relationships and provides the foundation to absorb fixed costs and pursue margin improvement as the business matures.
Read all positive factors
RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£11.17M
Dividend YieldN/A
Average Volume (3M)148.53K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.10M
RUA Life Sciences Business Overview & Revenue Model
Company Description
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of med...
How the Company Makes Money
null...
RUA Life Sciences Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.46M | 4.11M | 2.19M | 2.18M | 1.63M |
| Gross Profit | 3.06M | 3.17M | 1.72M | 1.43M | 1.04M |
| EBITDA | -383.33K | 401.00K | -1.57M | -1.95M | -2.04M |
| Net Income | -145.33K | 1.00K | -1.44M | -2.00M | -2.07M |
Balance Sheet | |||||
| Total Assets | 9.12M | 9.26M | 8.17M | 5.66M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 3.57M | 3.93M | 1.48M | 2.96M |
| Total Debt | 794.00K | 1.03M | 389.00K | 475.00K | 344.00K |
| Total Liabilities | 1.89M | 1.86M | 987.00K | 980.00K | 1.04M |
| Stockholders Equity | 7.14M | 7.30M | 7.18M | 4.68M | 6.58M |
Cash Flow | |||||
| Free Cash Flow | -298.00K | -281.00K | -1.38M | -1.62M | -3.27M |
| Operating Cash Flow | -137.00K | -219.00K | -1.33M | -1.17M | -2.36M |
| Investing Cash Flow | -59.00K | 70.00K | -85.00K | -449.00K | -904.00K |
| Financing Cash Flow | -459.00K | -196.00K | 3.89M | 132.00K | -66.00K |
RUA Life Sciences Technical Analysis
Positive
14.00
Price Trends
18.26
Positive
16.12
Positive
14.03
Positive
Market Momentum
-0.10
Positive
50.67
Neutral
34.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 14 is below the 20-day moving average (MA) of 21.45, below the 50-day MA of 18.26, and below the 200-day MA of 14.03, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.67 is Neutral, neither overbought nor oversold. The STOCH value of 34.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.
RUA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | £11.17M | -85.40 | 0.08% | ― | ― | ― | |
58 Neutral | £61.76M | 10.71 | 9.56% | ― | ― | ― | |
52 Neutral | £23.76M | -2.08 | -69.35% | ― | 31.78% | 10.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £4.43M | -4.86 | -16.78% | ― | -2.87% | 52.38% | |
49 Neutral | £19.67M | -1.98 | -153.92% | ― | 65.60% | 74.84% | |
49 Neutral | £6.46M | -1.66 | -2.42% | ― | 34.02% | -93.85% |
* Healthcare Sector Average
GB:RUA
RUA Life Sciences
20.00
8.25
70.21%
GB:CREO
Creo Medical
13.75
-2.25
-14.06%
GB:GDR
Genedrive
1.25
-0.13
-9.62%
GB:IHC
Inspiration Healthcare
26.50
5.50
26.19%
GB:OPTI
OptiBiotix Health
6.25
-6.75
-51.92%
GB:SUN
Surgical Innovations
0.48
-0.22
-32.14%
RUA Life Sciences Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
RUA Life Sciences Edges to EBITDA Breakeven as CDMO Growth Offsets Abiss Slowdown
Positive
May 22, 2026
RUA Life Sciences expects to report 6% revenue growth to £2.8 million for the six months to 31 March 2026, driven by a 32% rise in UK CDMO revenues and a 41% increase in biomaterials income, despite a 23% sales decline at Abiss caused by inve...
Business Operations and StrategyPrivate Placements and Financing
RUA Life Sciences spins out valve unit as Leducq leads £3m funding for AurTex mitral programme
Positive
May 12, 2026
RUA Life Sciences has spun out its subsidiary RUA Structural Heart and completed a £3 million convertible funding round led by the Leducq organization, alongside capitalising £4.8 million of intercompany debt into similar loan stock. RUA...
Business Operations and StrategyShareholder Meetings
RUA Life Sciences Secures Strong Shareholder Backing at AGM
Positive
Mar 17, 2026
RUA Life Sciences announced that all resolutions proposed at its latest Annual General Meeting were duly passed by shareholders with strong majorities. The voting outcomes, which showed high levels of support and minimal opposition across all 14 r...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
RUA Life Sciences flags growth inflection as CDMO pipeline builds and heart valve deal nears
Positive
Mar 17, 2026
RUA Life Sciences reported that activity in its UK contract development and manufacturing arm remains strong, with two main manufacturing contracts underpinning revenue and a growing pipeline of development work worth about £500,000 expected ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.